PMGC subsidiaries advance drug discovery program and achieve AS9100 certification

PMGC Holdings Inc.

NorthStrive Biosciences advances to Phase III of AI drug discovery program with YuvaBio, targeting muscle preservation via mitochondrial function.
Phase III will generate biological data on AI-selected compounds, including cytotoxicity screening and ANT1 expression testing over 6-9 weeks.
AGA Precision Systems achieves AS9100 certification, the globally recognized quality standard for aerospace, defense, and space industries.
AGA is evaluating humanoid robotics integration for advanced manufacturing; no assurance of implementation or benefits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.